Hepatitis B testing and growth in tree shrew as animal model
AssigneeBattelle-Institut e.V.
InventorsPeter Lorenz, Anita Schwaier
Life of this patent
Estimating the term…
Abstract
Tree shrews (Tupaia belangeri) are used as an animal model to test the inactivation of vaccines, the harmlessness of blood products and the effectiveness of chemotherapeutic agents and disinfectants against viral hepatitis. The antibody determinations are performed at specific intervals for a period of 150 days in the case of viral hepatitis type A and 60 days in the case of viral hepatitis type B.
Claims21
Process for the growth and collection of viral hepatitis antigen type B from a tree shrew (Tupaia belangeri), which is used as an animal model, comprising:
- (a) infecting said tree shrew with viral hepatitis type B;
- (b) performing at least one antibody determination at specific intervals over a period of about 60 days after infection of said tree shrew;
- and
- (c) obtaining said viral hepatitis antigen type B from said infected tree shrew.
Process for testing the effectiveness of a disinfectant against viral hepatitis type B comprising:
- (a) admixing a specific quantity of said viral hepatitis type B to form a suspension;
- (b) removing said viral hepatitis type B from said suspension;
- (c) admixing said viral hepatitis type B from step (b) with a physiological buffer to form a suspension;
- (d) vaccinating a tree shrew (Tupaia belangeri), which is used as an animal model, with the suspension from step (c);
- and
- (e) performing at least one antibody determination at specific intervals over a period of about 60 days after infection of said tree shrew,
- whereby said disinfectant is determined to be effective or ineffective against said viral hepatitis type B if said tree shrew, respectively, does not contract viral hepatitis or does contract viral hepatitis.
Process for testing the antiviral effectiveness of a chemotherapeutic agent against viral hepatitis type B comprising:
- (a) infecting a tree shrew (Tupaia belangeri), which is used as an animal model, with viral hepatitis type B;
- (b) administering said chemotherapeutic agent to said infected tree shrew;
- and
- (c) performing at least one antibody determination at specific intervals over a period of about 60 days after infection of said tree shrew,
- whereby said chemotherapeutic agent is determined to be ineffective against said viral hepatitis type B if said antibody determination detects anti-HBcAg antibody in said tree shrew.
Process for testing for the absence of viral hepatitis type B in blood products comprising:
- (a) administering said blood product to a tree shrew (Tupaia belangeri), which is used as an animal model, with viral hepatitis type B;
- and
- (b) performing at least one antibody determination at specific intervals over a period of about 60 days after infection of said tree shrew,
- whereby said blood product is determined to contain said viral hepatitis type B if said antibody determination detects anti-HBcAg antibody in said tree shrew.
Process for testing the antiviral ineffectiveness of a vaccine against viral hepatitis type B comprising:
- (a) infecting a tree shrew (Tupaia belangeri), which is used as an animal model, with viral hepatitis type B;
- (b) administering said vaccine to said infected tree shrew;
- and
- (c) performing at least one antibody determination at specific intervals over a period of about 60 days after infection of said tree shrew,
- whereby said vaccine is determined to be ineffective against said viral hepatitis type B if said antibody determination detects anti-HBcAg antibody in said tree shrew.
Dependencies are inferred from the claim text.